Commentary on research to improve contraceptive and multipurpose prevention technologies.

This commentary makes the case for increased investment in the development of improved contraceptive and multipurpose prevention technologies (MPTs) that better meet the needs and preferences of users, increase the methods' acceptability and use, and ultimately decrease unintended pregnancy. Methods that are inexpensive, user-controlled, and shelf-stable could help address challenges posed by weak supply chains and healthcare systems. New MPTs that protect against pregnancy and sexually transmitted infections (STIs), including HIV, could simultaneously address multiple sexual and reproductive health needs. Although promising scientific leads exist, the high costs and risks associated with contraceptive development has contributed to underinvestment. The public sector, philanthropies, and the pharmaceutical industry have decreased or eliminated investments in contraceptive research and development (R&D) in recent decades. Greater financial and policy support are required for the eventual introduction of new and improved contraceptives and MPTs. [ABSTRACT FROM AUTHOR]